Barrett's esophagus in 2012: updates in pathogenesis, treatment, and surveillance.

Subhash Chandra, Emmanuel C. Gorospe, Cadman Leggett, Kenneth Ke Ning Wang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Barrett's esophagus (BE) is the only established precursor lesion in the development of esophageal adenocarcinoma (EAC) and it increases the risk of cancer by 11-fold. It is regarded as a complication of gastroesophageal reflux disease. There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated dysplasia. In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years. It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease. For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated. In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE.

Original languageEnglish (US)
Pages (from-to)322
Number of pages1
JournalCurrent Gastroenterology Reports
Volume15
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Barrett Esophagus
Adenocarcinoma
Therapeutics
Molecular Imaging
Gastroesophageal Reflux
Biomarkers
Growth
Research
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Barrett's esophagus in 2012 : updates in pathogenesis, treatment, and surveillance. / Chandra, Subhash; Gorospe, Emmanuel C.; Leggett, Cadman; Wang, Kenneth Ke Ning.

In: Current Gastroenterology Reports, Vol. 15, No. 5, 05.2013, p. 322.

Research output: Contribution to journalArticle

@article{d009251e3f3d4ba5b703989ac1f2227e,
title = "Barrett's esophagus in 2012: updates in pathogenesis, treatment, and surveillance.",
abstract = "Barrett's esophagus (BE) is the only established precursor lesion in the development of esophageal adenocarcinoma (EAC) and it increases the risk of cancer by 11-fold. It is regarded as a complication of gastroesophageal reflux disease. There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated dysplasia. In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years. It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease. For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated. In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE.",
author = "Subhash Chandra and Gorospe, {Emmanuel C.} and Cadman Leggett and Wang, {Kenneth Ke Ning}",
year = "2013",
month = "5",
doi = "10.1007/s11894-013-0322-8",
language = "English (US)",
volume = "15",
pages = "322",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Barrett's esophagus in 2012

T2 - updates in pathogenesis, treatment, and surveillance.

AU - Chandra, Subhash

AU - Gorospe, Emmanuel C.

AU - Leggett, Cadman

AU - Wang, Kenneth Ke Ning

PY - 2013/5

Y1 - 2013/5

N2 - Barrett's esophagus (BE) is the only established precursor lesion in the development of esophageal adenocarcinoma (EAC) and it increases the risk of cancer by 11-fold. It is regarded as a complication of gastroesophageal reflux disease. There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated dysplasia. In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years. It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease. For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated. In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE.

AB - Barrett's esophagus (BE) is the only established precursor lesion in the development of esophageal adenocarcinoma (EAC) and it increases the risk of cancer by 11-fold. It is regarded as a complication of gastroesophageal reflux disease. There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated dysplasia. In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years. It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease. For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated. In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE.

UR - http://www.scopus.com/inward/record.url?scp=84884271739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884271739&partnerID=8YFLogxK

U2 - 10.1007/s11894-013-0322-8

DO - 10.1007/s11894-013-0322-8

M3 - Article

C2 - 23605564

AN - SCOPUS:84876196825

VL - 15

SP - 322

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 5

ER -